Enzymotec Ltd. (NASDAQ:ENZY) is set to issue its quarterly earnings data before the market opens on Tuesday, November 14th. Analysts expect the company to announce earnings of $0.10 per share for the quarter.

Enzymotec (NASDAQ:ENZY) last released its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by ($0.15). The firm had revenue of $13.00 million for the quarter, compared to analysts’ expectations of $12.78 million. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.04 EPS. On average, analysts expect Enzymotec to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Enzymotec Ltd. (NASDAQ:ENZY) opened at $11.80 on Monday. Enzymotec Ltd. has a 12-month low of $5.20 and a 12-month high of $12.35.

COPYRIGHT VIOLATION WARNING: “Enzymotec Ltd. (ENZY) Scheduled to Post Quarterly Earnings on Tuesday” was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/12/enzymotec-ltd-enzy-scheduled-to-post-quarterly-earnings-on-tuesday.html.

An institutional investor recently raised its position in Enzymotec stock. State Street Corp raised its position in Enzymotec Ltd. (NASDAQ:ENZY) by 1.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,952 shares of the biotechnology company’s stock after purchasing an additional 380 shares during the quarter. State Street Corp owned 0.09% of Enzymotec worth $169,000 as of its most recent SEC filing. 26.46% of the stock is currently owned by institutional investors.

Several research firms have recently commented on ENZY. Zacks Investment Research raised shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. ValuEngine raised shares of Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Jefferies Group LLC reaffirmed a “hold” rating and set a $11.50 price target on shares of Enzymotec in a research report on Thursday, October 19th. Finally, Wells Fargo & Company boosted their target price on Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research report on Monday, October 30th. Four research analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and a consensus target price of $11.75.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Earnings History for Enzymotec (NASDAQ:ENZY)

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.